Los Angeles Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Los Angeles Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,347	Closed	-$238K	–	1529
2021 Q3	$238K	Buy	+1,347	New	+$217K	﹤0.01%	1381
2021 Q2	–	Sell	-9,562	Closed	-$1.64M	–	1705
2021 Q1	$1.64M	Sell	9,562 -10,112	-51%	-$2M	0.01%	686
2020 Q4	$4.32M	Sell	19,674 -319	-2%	-$69K	0.02%	429
2020 Q3	$3.32M	Sell	19,993 -6,054	-23%	-$828K	0.02%	423
2020 Q2	$2.97M	Buy	+26,047	New	+$2.53M	0.01%	512

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Los Angeles Capital Management's MRTX Position: Q4 2021 in Review

Los Angeles Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 1,347 shares — an estimated $238K sold.

Los Angeles Capital Management first reported a position in MRTX in Q2 2020 and held it in 5 quarters. The position peaked at $4.32M in Q4 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

Los Angeles Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Los Angeles Capital Management sold 1,347 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $238K.
Los Angeles Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
Los Angeles Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $4.32M in Q4 2020.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Los Angeles Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.